© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Decades ago, type 2 diabetes pressed clinicians and researchers to hunt for more targeted therapies as older drugs often led to side effects and did not always address complex glucose regulation. The journey to saxagliptin monohydrate began with the discovery of the DPP-4 (dipeptidyl peptidase-4) enzyme, a regulator in glucose metabolism. Once scientists linked DPP-4 activity with impaired incretin signaling and poor glycemic control, several companies poured energy and resources into building molecules that could block this enzyme. In the mid-2000s, saxagliptin, developed by Bristol-Myers Squibb with AstraZeneca, reached the market, providing fresh hope for people living with diabetes. The monohydrate form, selected for its stable, crystalline properties, brought improvements in manufacturing and handling, addressing storage and formulation hurdles that plagued earlier candidates.
Known on pharmacy shelves as Onglyza, saxagliptin monohydrate serves as an oral antidiabetic meant to help adults with type 2 diabetes achieve better blood sugar control. Containing a single water molecule within its crystal structure, this form offers more consistent dosage and improved shelf stability. Its formulation allows for tablets that preserve drug integrity through everyday storage conditions, a crucial trait for medicines stored at home and transported across climates. The ability to pair saxagliptin with other antidiabetic agents, like metformin, makes it valuable in multi-drug regimens. Brand names may shift across geographies and generic competition, but the reliability of the monohydrate form secures its central role in therapy.
Take a close look at saxagliptin monohydrate’s properties: it comes as a white to off-white crystalline powder. It dissolves well in water and slightly in ethanol, an advantage for oral use. Chemically, its molecular formula is C18H25N3O2•H2O with a molecular weight near 351.43 g/mol. Its melting range and moisture content remain consistent between batches, thanks to well-defined preparation steps. The addition of a water molecule as monohydrate locks the crystal lattice, reducing the risk of unwanted transformations during tablet compaction or long-term storage. Its pKa, logP, and solubility profiles are measured carefully, as slight shifts can impact how much drug reaches the bloodstream and, eventually, the glucose-lowering effect.
Manufacturers standardize each batch of saxagliptin monohydrate through strict reference to pharmacopeia standards and regulatory guidance. Each tablet contains an exact dosage, usually 2.5 mg or 5 mg, while excipients ensure both purity and uniform release in the body. Regulatory filings detail allowed moisture, impurities, particle size, and dissolution rates. Labels list batch numbers, expiration dates, and instructions for use, providing patients and pharmacists with straightforward guidelines. Storage instructions often state to keep the medicine below a certain temperature, dry, and away from light, emphasizing the care needed to maintain its effects. Package inserts dig deep into side effects, interaction risks, and steps to take if doses are missed, equipping users to stay safe and informed.
Turning raw materials into therapeutic-grade saxagliptin monohydrate takes multiple chemical steps. Starting with a well-chosen precursor scaffold, chemists build the pyrrolidine and adamantyl groups, then selectively protect and deprotect amine and nitrile functions. Water is introduced precisely during a final crystallization stage, locking in the monohydrate form without triggering degradation. Careful purification, often through recrystallization or chromatography, follows. Lab teams sample each batch, running infrared and X-ray analyses to confirm the correct crystal form and absence of undesired isomers. The last step, tableting, blends the active ingredient with binders and disintegrants before pressing and coating.
Saxagliptin’s synthesis relies on stepwise formation of its adamantyl and pyrrolidine rings, connected by precision-controlled carbon-nitrogen bonds. The introduction of a cyano substituent is delicate—too harsh a reagent or solvent skewers yield and purity. During development, chemists tweaked side chains and protecting groups, searching for a balance between potency, selectivity, and metabolic stability. Modifications to the molecule may fine-tune half-life or bioavailability, always with an eye toward patient convenience and safety. Later research explored alternative salt forms or prodrugs, but the monohydrate came out ahead for reasons rooted in real-world handling and storage.
Alongside the internationally recognized name saxagliptin monohydrate, other names are often seen in regulatory filings and chemical registries. Chemical texts may cite it as BMS-477118 monohydrate or use descriptors connected to its structure, such as (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile monohydrate. The key brand, Onglyza, remains familiar in clinics, though generic entries bring new packaging and sometimes different pill appearances.
Manufacturing facilities operate under current Good Manufacturing Practices (cGMP), so every saxagliptin tablet produced meets FDA and EMA standards. Workers wear personal protective equipment, and production lines monitor airborne dust and humidity to prevent cross-contamination or loss of precision. Pharmacovigilance teams track adverse reports and update risk management plans as new data emerges. Warning labels highlight rare but serious side effects, such as pancreatitis and joint pain, and urge clinicians to adjust dosages in people with kidney impairment. The clear safety profile stands on years of post-market surveillance, showing that saxagliptin rarely causes hypoglycemia when taken without insulin or sulfonylureas.
Doctors prescribe saxagliptin monohydrate for adults with type 2 diabetes whose blood sugar remains high despite diet and exercise. It fits well for people struggling with overweight or cardiovascular risk, as clinical studies show little effect on body weight and low risk for low blood sugar. Some combinations with other pills support tougher-to-control cases, and guidelines now include DPP-4 inhibitors as an option for many newly diagnosed patients. Many health systems have added it to formularies based on its manageable side-effect profile and convenient dosing. Researchers weighing broader DPP-4 utility have explored uses in other metabolic conditions, yet diabetes stays its mainstay for now.
Every drug on the shelf began as an unknown chemical, and saxagliptin’s path from the lab to the clinic demanded years of careful optimization. Early in discovery, teams screened related molecules in enzymatic and animal models, accumulating reams of data to winnow out those with poor absorption, toxicity, or weak DPP-4 inhibition. Once saxagliptin showed promise, clinical work ramped up, testing for differences between tablets, food impact, patient subgroups, and safety in varied populations. Ongoing post-approval surveillance refines our view, with long-term studies examining cardiac events and rare side effects. Academic groups continue to update best practices for titrating doses, mixing therapies, and attending to patients' other diseases, sparking collaborative progress year after year.
Toxicologists probed saxagliptin’s short- and long-term effects long before it reached the market. Preclinical trials in animals mapped doses that cause organ changes, behavior shifts, or biochemical disruptions. Later human studies monitored potential for liver, kidney, or cardiac harm, always comparing to control groups. Data showed the drug generally passes through the body without buildup or lasting injury, though certain populations need lower doses due to slower breakdown. Detailed reviews surfaced a handful of rare complications, including immune system flare-ups or pancreas inflammation, leading to stronger warnings and research into risk factors. The collective knowledge to date points to careful monitoring, especially when patients carry multiple coexisting conditions.
Looking ahead, the role of saxagliptin monohydrate in diabetes care will keep evolving with better ways to monitor and personalize therapy. Digital health tools, such as blood glucose trackers and telemedicine, could knit DPP-4 inhibitors into larger management programs. Patent expirations spur more generic entrants, pushing costs down and access up across low- and middle-income countries. Researchers continue to chase next-generation molecules with even fewer side effects and once-weekly dosing, but as of now, saxagliptin’s efficacy and safety mark it as a reliable pillar for many. Fresh research may reveal new indications or added benefits when paired with SGLT-2 inhibitors or GLP-1 agonists, reflecting medicine’s ongoing drive to refine care for those facing chronic illness.
Saxagliptin Monohydrate pops up a lot in conversations about type 2 diabetes. People struggle every day to keep blood sugar in check, and for many, food choices and exercise just don't cut it. Doctors often turn to medication for support, and that's where drugs like saxagliptin monohydrate step in. This medicine doesn’t replace insulin, and it isn’t a cure. Instead, it helps people use their own insulin more effectively, mainly after eating.
This compound falls under a group called DPP-4 inhibitors. DPP-4 stands for dipeptidyl peptidase-4, an enzyme in the body that breaks down hormones involved in insulin release. By blocking that enzyme, saxagliptin lets those helpful hormones stick around longer, making it easier for the pancreas to release insulin right after meals. Blood sugar spikes get softened. For a lot of patients, that takes away some of the stress and harsh swings they might see on the glucose meter each day.
I've seen how tough diabetes management can get, especially after diagnosis. Folks want real solutions, not just pep talks about willpower. Saxagliptin monohydrate gives doctors a serious tool when diet changes don’t move the numbers much. In large studies, people taking DPP-4 inhibitors saw better control of their blood sugar than those who used lifestyle changes alone. This doesn't mean everyone drops their other meds. Usually, saxagliptin gets added when metformin or similar drugs can’t do enough on their own. It doesn’t push the body to make more insulin than it should, so folks see a much lower risk of their sugar dropping too low—something that turns a lot of people off from some older diabetes treatments.
Still, using saxagliptin isn’t a free pass. It works best when people combine it with good meals and regular physical activity. Side effects exist. Most aren’t severe, but any medicine that plays with hormone pathways deserves respect and careful monitoring. Doctors keep an eye out for unusual infections and, more rarely, heart problems. This means offices and labs become part of life for anyone on saxagliptin.
One big hurdle I’ve watched families deal with is getting hold of these newer medicines. Cost gets in the way for too many people. Insurance covers saxagliptin sometimes, but not always, and out-of-pocket prices can sting. Generic options and patient assistance programs help some, but not enough. If more people could get this medication, fewer would end up dealing with the long-term damage of out-of-control diabetes—kidney issues, vision loss, and so on.
Doctors also need to explain, every step along the way, why a certain medicine lands on a prescription pad. People tend to take their treatment plans more seriously when they know how and why a drug works for them personally. Health systems benefit when patients and providers work as partners, not opponents. For saxagliptin and other DPP-4 blockers, the best results show up when folks understand the trade-offs and get the support they need to deal with costs and side effects.
Type 2 diabetes keeps growing. No single fix will turn the tide, but for people stuck between diet and full-on insulin injections, saxagliptin monohydrate can keep things steadier. As healthcare keeps changing, figuring out better ways to get tools like this into patient hands—without crushing them under costs—remains a top priority.
Diabetes brings a bag of worries. Staying on top of blood sugar levels, meals, work—nothing feels simple. You grab a prescription for Saxagliptin Monohydrate. The pharmacist rattles off a list of side effects, and you head home, hoping for the best. It's easy to treat these warnings as background noise, but they do matter. Figuring out what to expect can make a real difference in daily living.
Saxagliptin Monohydrate works as a DPP-4 inhibitor; it helps your body control blood sugar. As with most medications, bodies respond in different ways. One of the most common issues is a headache—not the kind you can sleep off or ignore at work. Irritation builds, and painkillers start to look like a staple. For some, the headaches fade as the weeks go on. In other people, they linger and make daily routines tougher.
Upper respiratory symptoms show up for many, too. We're talking about runny nose, sneezing, sore throat—things you might shrug off during allergy season. It gets old quickly when they go on and on. For a group already trying to manage fatigue and the weight of diabetes, these extra symptoms can push the limit of patience.
Nausea hits some users. It's not as dramatic as the stomach flu, but it saps appetite and can make meal planning exhausting. Juggling blood sugar and eating enough is already a balancing act. I remember my own relative leaving half her lunch untouched, feeling queasy on certain afternoons. She started splitting meals into smaller portions, finding what worked by trial and error. Not every fix is perfect, but a little creativity keeps nutrition and comfort closer in reach.
Stomach pain or indigestion crops up occasionally. Sometimes, the discomfort settles after a few weeks. Other times, people feel like they’re constantly dodging heartburn. Bringing this up with a doctor leads to better strategies—maybe switching when you take the pill or adjusting diet just a little.
There’s word in research about joint pain and allergic reactions, often reported through FDA monitoring. Skin rash, swelling of the face or throat, and severe joint aches—these don’t show up in everybody, but ignoring them carries real risk. For anyone who spots these red flags, prompt attention gives better outcomes. Hard to overstate the role of quick reaction here. Trusting your gut—if it feels wrong, don’t wait.
A few studies also mention urinary tract infections. Needing to pee more often and pain during urination can be written off as small annoyances. Still, infections left unaddressed don't just fade; they can land someone in the hospital. Monitoring these symptoms and looping in your provider keeps things safer.
Routine blood tests and honest conversations with your healthcare provider act as the best safeguard. Adjusting other medications, changing the time of your doses, or trying a different meal plan—all of these can ease the burden. No one should accept daily misery as the price of better blood sugar readings.
At the core, Saxagliptin Monohydrate provides many with real relief from uncontrolled diabetes. Being open about side effects gives us a shot at handling them early. Healthcare teams can only help with what they know, so talking about what the body goes through isn't complaining—it's part of the process.
Living with type 2 diabetes changes daily routines. Medications often become part of that change. Saxagliptin monohydrate, a DPP-4 inhibitor, works with a body’s own chemicals to help manage blood sugar levels. Missing doses or taking medicine at the wrong time can mess with how well this treatment works. From spending years talking to people in clinics, I’ve seen that learning the simple steps for taking medicine often gets overlooked. It shouldn’t be.
Doctors usually recommend taking saxagliptin once a day. Picking a regular time—right after brushing teeth in the morning or before sitting down to breakfast—helps create a routine. Keeping this medication near other daily essentials makes it harder to forget. The tablet can go down with or without food, so the routine doesn’t have to change much even on busy days.
Some folks dislike swallowing tablets. Saxagliptin tablets do not get crushed or chewed, as this can upset how the drug works in the body. Swallow it whole with water. One nurse shared with me that she tells her patients to drink a full glass of water with each dose—less about science, more about building a ritual that makes the medicine go down easier.
Diabetes isn’t just about numbers on a meter. Saxagliptin may help steady blood sugar, but only if you know what’s happening with your body. Doctors want to see regular tests of kidney function before and during treatment. That’s not red tape. One patient learned his kidneys couldn’t handle the standard dose, and his doctor caught the problem before it became serious. Honest conversations with health professionals keep the risks low.
Alcohol can worsen blood sugar swings and put more stress on organs. Try to limit it. Always tell your pharmacist about any new prescriptions or supplements. Some drugs, like strong antibiotics or antifungals, can clash with saxagliptin and lead to side effects. A family friend once mixed over-the-counter cold medicine with her diabetes medication without asking anyone—she ended up lightheaded and confused. Double-checking, even if it feels minor, helps dodge these problems.
Everybody forgets once in a while. If a dose gets missed, take it the moment you remember unless it’s almost time for the next tablet. Don’t double up. Small daily habits help; using a pill organizer or setting an alarm on a phone keeps things on track. I’ve watched older relatives write reminders on the fridge or use sticky notes. Simple, old-school methods work.
Some people get headaches, chest pain, or infections in their nose or throat. More rarely, others notice swelling in their feet or hands. While symptoms like these cause worry, doctors want to know about changes, small or big. Keeping an open line of communication helps find fixes faster.
If swelling in the face, lips, or throat happens, that’s not something to wait on—head to a clinic or call for help. Same goes for signs of low blood sugar: sweating, confusion, or shakiness. These emergencies need quick action.
Saxagliptin can only do its job if people stay on it, keep an eye on their overall health, and talk openly with their healthcare teams. Everyday habits and direct, clear conversations make a real difference. In the long run, that’s the foundation for managing diabetes, no matter which medication gets prescribed.
Drug combinations for diabetes spark big questions and sometimes a little worry. Mixing pills isn’t just about chasing a lower blood sugar number—it’s about everyday life. Most people with type 2 diabetes eventually need more than one medication. Saxagliptin monohydrate, a DPP-4 inhibitor, draws notice because it comes with its own pros and cons. Sharing insights makes this topic less foggy, so let’s talk about it plainly with real-world sense and scientific footing.
Saxagliptin monohydrate manages sugar mainly by blocking DPP-4, an enzyme that breaks down incretin hormones. These hormones keep the pancreas tuned to meals and food intake. They tell the body to make more insulin and put the brakes on glucose leaking out from the liver. But no single medicine solves everything. Metformin comes first for most—it’s a workhorse for both cost and results. Metformin’s big advantage is lowering the sugar dump from your liver and making muscles use sugar better. Saxagliptin steps in when those first efforts just don’t cut it, especially in adults whose blood sugar refuses to budge.
Adding saxagliptin feels like a natural next step for many. Doctors across the globe pair it with metformin, sulfonylureas, or insulin if one drug can’t tackle high blood sugar alone. The FDA and global health bodies give this combo the green light under supervision. I’ve seen friends and relatives use combinations like this for years—usually metformin and a DPP-4 inhibitor—without major drama, but adjusting doses matters. Digging into the evidence, one large study found a three-way combo—metformin, saxagliptin, and sulfonylureas—gently lowers average blood sugar levels and keeps the risk of weight gain smaller than many older drugs. You don’t get sudden sugar crashes as often, and the routine feels less wild from day to day.
Drug pairing doesn’t mean there’s zero risk. Some folks run into side effects easier with combination therapy. Think of swelling in hands or feet, a slower kidney, or rare but possible pancreas irritation. Combining a DPP-4 blocker like saxagliptin with insulin or sulfonylureas can bump up the chance of low blood sugar episodes. Older adults and anyone with kidney slowdowns face extra risk because the drug stays in the system longer. Since diabetes also brings other health challenges—sometimes heart or kidney trouble clutter the scene—it takes close medical follow-up and lab checks to avoid harm. People should always raise new symptoms with their clinicians right away. Families and patients just want to know the risks aren’t hidden and support is on hand at every step.
No two diabetes cases are identical. Doctors shouldn’t just toss names of medicines together. They should get the full picture—kidney health, eating habits, weight, and past reactions to drugs. Guidelines say routine should not win over personalization. New tools like continuous glucose monitoring help tailor plans, catching sugar swings early. Education makes a difference, too, since understanding your own routine means fewer surprises. It helps to ask questions and use pharmacist advice, because sometimes drug lists grow complicated fast.
Saxagliptin monohydrate brings useful options after metformin alone hits a wall. The trick is teamwork—doctors and patients sharing decisions, careful monitoring, and open talk about all prescription routines. Addressing side effects quickly, checking kidneys, and changing gears if goals aren’t met all help make combination therapy productive instead of stressful. Diabetes care marches ahead step-by-step, not all at once.
Doctors prescribe Saxagliptin Monohydrate to help manage blood sugar in adults with type 2 diabetes. It’s part of a class called DPP-4 inhibitors. The risks with a medication like this don’t always jump out at the pharmacy counter, but they matter all the same. A decade back, a friend invited me along to a support group for folks living with diabetes; all ages, all backgrounds, some on Saxagliptin. People asked sharp questions about side effects and long-term safety. Turns out, they had good reason.
Several large clinical trials in recent years highlight a few sticking points. One real concern? Saxagliptin may raise the risk of heart failure in some individuals. The SAVOR-TIMI 53 trial laid it out in black and white: more people on Saxagliptin ended up hospitalized for heart failure compared to those who got a placebo. This should put a pause on automatic renewals, especially for patients already dealing with heart trouble. Cardiologists keep looking at this class of drugs with a critical eye.
Another issue involves immune system function. DPP-4 inhibitors, including Saxagliptin, can nudge up the likelihood of respiratory infections and urinary tract infections. I remember a retired teacher from my town who switched drugs after her second UTI in two months. Her nurse pinpointed her medication after reading the latest data. For patients with a weakened immune system, knowing these risks early on means fewer surprises and better collaboration with the healthcare team.
A handful of people taking Saxagliptin have developed serious inflammation of the pancreas, called pancreatitis. Symptoms come on fast: severe belly pain, vomiting, sometimes fever. The FDA has issued warnings about this side effect. If signs crop up, a trip to the ER can’t wait. Anyone with a history of pancreatitis or gallstones should keep this possibility front and center in talks with a physician.
Severe allergic reactions can happen in rare cases—skin rashes, swelling around the face, or trouble breathing. These need immediate attention. The risk isn’t high, but it stands as one reason to watch closely during the first few weeks after starting the drug.
No diabetes medication acts in a vacuum; Saxagliptin interacts with other drugs in ways that change how it works or increases side effects. Some antibiotics and anti-fungal meds can raise Saxagliptin levels in the bloodstream. People with advanced kidney disease process this drug much more slowly, so doctors adjust the dosage. Patients should tell their providers about every single pill—prescription or otherwise—to keep things safe.
Blood sugar can drop too low if Saxagliptin teams up with insulin or sulfonylureas. These low blood sugar episodes leave folks shaky, weak, or confused. Logging snacks, keeping glucose tablets on hand, and honest communication with a provider protect against these surprises.
Strong safety comes from clear information and real teamwork. Open dialogue between patient and provider makes a difference: regular check-ins, sharing any new symptoms, and checking lab numbers. The American Diabetes Association and FDA websites carry up-to-date warnings and safety tips, valuable resources for anyone using Saxagliptin. Bringing a family member or friend to appointments can help catch side effects sooner and gives extra peace of mind.
| Names | |
| Preferred IUPAC name | (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile monohydrate |
| Other names |
Onglyza BMS-477118 Saxagliptin hydrate |
| Pronunciation | /ˌsæksəˈɡlɪptɪn ˌmɒnəʊˈhaɪdreɪt/ |
| Identifiers | |
| CAS Number | 945667-22-1 |
| Beilstein Reference | 1432304 |
| ChEBI | CHEBI:133012 |
| ChEMBL | CHEMBL1254898 |
| ChemSpider | 138538034 |
| DrugBank | DB06335 |
| ECHA InfoCard | 07e0913d-637a-4cd1-9462-76f6df4c16fc |
| EC Number | Not assigned |
| Gmelin Reference | 1730694 |
| KEGG | D08914 |
| MeSH | Dipeptidyl-Peptidase IV Inhibitors |
| PubChem CID | 71200067 |
| RTECS number | WH723T7D0A |
| UNII | NA9B639RAJ |
| UN number | Not assigned |
| CompTox Dashboard (EPA) | DTXSID40116214 |
| Properties | |
| Chemical formula | C18H25N3O2·H2O |
| Molar mass | 441.45 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Freely soluble |
| log P | 1.2 |
| Acidity (pKa) | 7.9 |
| Basicity (pKb) | 7.7 |
| Dipole moment | 5.82 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 252.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | A10BH03 |
| Hazards | |
| Main hazards | May cause allergic reactions, acute pancreatitis, hypoglycemia (when used with insulin or sulfonylureas), severe joint pain, and heart failure. |
| GHS labelling | GHS labelling: Danger; H302, H315, H319, H335; P261, P305+P351+P338, P405, P501 |
| Pictograms | Rx;℞;Prescription only;Oral;Tablet;Antidiabetic;DPP-4 inhibitor |
| Signal word | No signal word |
| Hazard statements | H302: Harmful if swallowed. H361: Suspected of damaging fertility or the unborn child. |
| Precautionary statements | Store protected from moisture at a temperature not exceeding 30°C. |
| Flash point | > 243.6 °C |
| Lethal dose or concentration | LD₅₀ (oral, rat) > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >5000 mg/kg (rat, oral) |
| NIOSH | DB08896 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 0.0005 |
| Related compounds | |
| Related compounds |
Saxagliptin Saxagliptin Hydrochloride Sitagliptin Vildagliptin Alogliptin Linagliptin Teneligliptin |
